decisionhealth Newsletters, Coder Pink Sheets - 2012 Issue 10 (October)
Web-only Exclusive: Be careful about recent CPT guidance on billing multiple Xiaflex injections
Subscribe or sign in to view the full article.
Article Overview
This premium article explains recent CPT-related guidance, FDA labeling, and payer-policy considerations for Xiaflex-associated injection services in Dupuytren’s contracture cases. It is intended for coders, billers, and reimbursement staff who need to understand how professional guidance, drug labeling, and payer edit policies may intersect for same-session treatment scenarios. The discussion focuses on general billing and compliance considerations without reproducing the full premium decision support.
Why This Topic Matters
The topic matters because coding and coverage guidance from professional sources, drug labeling, and payer edits may not align, creating potential compliance and reimbursement risk for practices that treat Dupuytren’s contracture.
What You Will Learn
- How recent CPT-related guidance is framed for Xiaflex-associated injection services
- How FDA labeling and payer policy considerations can affect billing review
- Why Medicare edit policies are relevant to same-date reporting
- How the article compares professional guidance with other sources of billing direction
Who Should Read This
- Medical coders
- Billing staff
- Compliance teams
- Practice administrators
- Orthopedic and hand-surgery billing specialists
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com